Partial volume corrected 18F-FDG PET mean standardized uptake value correlates with prognostic factors in breast cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 58, Issue 4, 2014, Pages 424-439

  Gallivanone, F ^a   Canevari, C ^b   Sassi, I ^b   Zuber, V ^b   Marassi, A ^b   Gianolli, L ^b   Picchio, M ^a,b   Messa, C ^a,c   Gilardi, M C ^a   Castiglioni, I ^a  

^a CNR   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Breast neoplasms; Fluorodeoxyglucose F18; Positron emission tomography; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY WEIGHT; BREAST CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; MIDDLE AGED; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; VERY ELDERLY; WHOLE BODY CT; BREAST TUMOR; CLUSTER ANALYSIS; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROGNOSIS; REGRESSION ANALYSIS; SCINTISCANNING; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BODY WEIGHT; BREAST NEOPLASMS; CLUSTER ANALYSIS; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAMMOGRAPHY; MIDDLE AGED; MODELS, STATISTICAL; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REGRESSION ANALYSIS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927960638     PISSN: 18244785     EISSN: 18271936     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hahn WC, Weinberg RA. Rules for making human rumor cells. N Engl J Med 2002;347:1593-603.
3. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet 2011;130:3-14.
4. Casado-Vela J, Cebrian A, Gomez Del Pulgar MT, Lacal JC. Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol 2011;13:617-28.
5. Bieche I. Search for new genes involved in breast tumorigenesis by "Omics" analysis. Bull Cancer 2012;97:1365-80.
6. Drake RR, Cazares LH, Jones EE, Fuller TW, Semmes OJ, Laronga C. Challenges to developing proteomic-based breast cancer diagnostics. OMICS 2011;15:251-9.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics. Cancer J Clin 2012;62:10-29.
8. Groheux D, Giacchetti S, Rubello D, Al-Nahhas A, Moretti JL, Espie M et al. The evolving role of PET/CT in breast cancer. Nucl Med Commun 2010;31:271-3.
9. 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38:426-35.
10. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 2004;3(Suppl 1):S135-142.
11. Fleming IN, Gilbert FJ, Miles KA, Cameron D. Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging 2010;10:144-52.
12. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger, K. Advantages and limitations of FDG PET in the follow-up if breast cancer. Eur J Nucl Med Mol Imaging 2004;3(Suppl. 1):S125-134.
13. 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging 2011;38:419-25.
14. Gilardi L, De Cicco C, Paganelli G. Preoperative FDG PET/CT in breast cancer patients: where are we going? Eur J Nucl Med Mol Imaging 2012;9:1667-9
15. 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 2012;26:175-83.
16. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging 2011;38:46-52.
17. Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 2010;15:588-93.
18. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010;51:543-50.
19. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
20. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer 2007; l4:260-8.
21. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-34.
22. 18F] fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 2009;6:166-70.
23. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112:995-1000.
24. 18F-FDG PET/CD in primary breast cancer. Jpn J Clin Oncol 2008;38:250-8.
25. Buck A, Schirrmeister H, Kiihn T, Shen C, Kalker T, Kotzerke J et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-23.
26. De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F et al. Is [(18) F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast 2012 [Epub ahead of print].
27. Sanli Y, Kuyumcu S, Ozkan ZG, Isik G, Karanlik H, Guzelbey B et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med 2012;26:345-50.
28. Soret M, Bacharach SL, Buvat I. Partial-Volume Effect in PET Tumor Imaging. J Nucl Med 2007;48:932-45.
29. Gallivanone F, Stefano A, Grosso E, Canevari C, Gianolli L, Messa C et al. PVE Correction in PET-CT Whole-Body Oncological Studies From PVE-Affected Images. IEEE Trans Nucl Sci 2011;58:736-47.
30. Bettinardi V, Mancosu P, Danna M, Giovacchini G, Landoni C, Picchio M et al. Two-dimensional vs.three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient'study. QJNucl Med Mol Imaging 2007;51:214-23.
31. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
32. Tavassoli FA, Devilee R World Health Organization Classification of Tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon, France, IARC Press; 2003.
33. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.
34. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.
35. Avril N, Schelling M, Dose J, Weber WA, Schwaiger M. Utility of PET in Breast Cancer. Clin Positron Imaging 1999;2:261-71.
36. Hodgson NC, Gulenchyn ICY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712-20.
37. Groheux D, Moretti JL, Giacchetti S, Hindie E, Teyton P, Cuvier C et al. PET/CT in breast cancer: an update. Bull Cancer 2009;96:1053-70.
38. Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 2004;42:1113-22.
39. Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of (18) F-FDG in the lactating breast. J Nucl Med 2001;42:1238-42.
40. Bakheet SM, Powe J, Kandil A, Ezzat A, Rostom A, Amartey J. F-18 FDG uptake in breast infection and inflammation. Clin Nucl Med 2000;25:100-3.
41. 18F-FDG PET/CT. AJR Am J Roentgenol 2011;197:341-7.
42. 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol 2012;53:518-23.
43. Rousseau C, Devillers A, Campone M, Campion L, Ferrer L, Sagan C et al. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging 2011;38:1029-36.
44. Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012;39:852-63.
45. 18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer. QJNucl Med Mol Imaging 2012;56:291-8.
46. Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET et al. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res 2012;2:34.
47. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ and Panel members. Thresholds for therapies: highlights'of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009;20:1319-29.
48. Tsuchiya S. Cytological characteristics of invasive lobular carcinoma of the human breast. Med Mol Morphol 2008;41:121-5.
49. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 2000;37:536-45.
50. Hoffman;EJ, Huang. SC, Phelps ME. Quantitation inypositron emission computed tomography: Effect of object size. J Comput Assist Tomogr 1979;3:299-308.